KRAS mutations are the most prevalent oncogenic drivers in NSCLC and frequently co-occur with mutations in TP53 and LKB1, which define subgroups of patients with distinct biology and therapeutic vulnerabilities [8]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.